Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
This meta-analysis of 53 previous randomized-controlled trials was done to compare erythopoietic agents plus red blood cell transfusions to transfusions alone in the management of anemia in patients with cancer. This study showed that treatment with erythropoiesis-stimulating agents resulted in increased mortality in patients with cancer.
- Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.
- The FDA’s Perspective on the Risk for Rapid Rise in Hemoglobin in Treating CKD Anemia: Quo Vadis
- Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease: A Systematic Review and Meta-analysis